The present invention relates to a phosphomimetic RAGE protein comprising an amino acid sequence that is at least 90% identical to a native mammalian RAGE isoform or fragment thereof wherein at least one serine present in the cytoplasmatic tail of the mammalian RAGE isoform is replaced by a phosphomimetic structure. The invention further relates to a polynucleotide encoding phosphomimetic RAGE protein and a vector comprising the polynucleotide. Finally, the invention relates to a composition comprising carrier and an active pharmaceutical ingredient, selected from the RAGE protein the vector for use in the treatment or prevention of a disease in a patient, wherein the disease is preferably selected from a disease initiated by impaired DNA repair, a disease initiated by increased DNA damage or a disease initiated by increased senescence.
The present invention provides method of studying an effect of a test substance on a test sample of bio-logical cells using a set of relevant parameters and a set of meta-features, the method comprising:
exposing the test sample to the test substance;
determining parameter values of the set of relevant parameters for each of a plurality of cells in the test sample; and
determining feature values of the set of meta-features for the test sample, wherein each of the feature values is calculated from the parameter values of a cluster of correlated parameters from the set of relevant parameters that is associated with the respective meta-feature,
wherein a reference sample for determining the set of meta-features was exposed to a stimulus substance.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
The invention relates to oral pharmaceutical compositions of an active agent and a lipid conjugate of a cell penetrating peptide conjugated to a lipid molecule. The conjugated lipid acts as a permeation enhancer for the active agent in the composition. In other words, oral bioavailability of the active agent increases when co-administered together with the lipid conjugate described herein.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Described herein is a method for identifying a subject suffering from a severe form of a metabolic disease, including a) obtaining (i) at least partial nucleic acid sequences of at least two alleles of a gene contributing to the metabolic disease or at least partial amino acid sequences of the polypeptides expressed therefrom; and (ii) a residual activity of the polypeptides expressed from the at least two alleles, and b) based on the result of step a), identifying a subject suffering from a severe form of a metabolic disease. Also described herein are methods, data collections, devices, kit, and computer program products related thereto.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Institut National de la Santé et de la Recherche Médicale (France)
Inventor
Buj Bello, Ana
Renaud-Gabardos, Edith
Grimm, Dirk
Weinmann, Jonas
Abstract
The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpol) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
7.
COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION
The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof:
The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof:
The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof:
wherein X and Y are independently selected from —CH2— and —O—, preferably are —CH2—; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R1 is, optionally substituted, C5-C6 cycloalkyl or aryl: R2 is, optionally substituted, aryl or heteroaryl; R3 and R4 are —H, or R3 and R4 together form a —CH2—CH2— bridge; R5 and R7 are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R6 is absent, or, in case Z is C, R6 together with R5 forms a —CH═CH—CH═CH— bridge; and/or (ii) a C—C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a method for preparing a compound T having a thioether group from a compound D having a disulfide group in the presence of a carbene.
The disclosure in particular relates to a ventricular assist device for implantation into a lumen of a blood vessel, comprising an impeller fixed to a rotor shaft, wherein the impeller is configured to rotate around a longitudinal axis of the rotor shaft; a drive unit comprising a magnetic motor configured to cause rotation of the impeller around to the longitudinal axis; a first active magnetic bearing configured to bear a first end section of the rotor shaft relative to the drive unit; a second active magnetic bearing configured to bear a second end section of the rotor shaft relative to the drive unit; and a control unit configured to control the magnetic motor, the first active magnetic bearing and the second active magnetic bearing.
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
11.
COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS
The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Germany)
Inventor
Nickel, Felix
Petersen, Jens
Onogur, Sinan
Schmidt, Mona
Kowalewski, Karl-Friedrich
Eisenmann, Matthias
Thiel, Christoph
Trent, Sarah
Weber, Christian
Abstract
The present disclosure provides a computer implemented method for facilitating a teaching surgeon to teach or assist a learning surgeon in minimally invasive interventions using a surgical instrument including displaying endoscopic images of an intervention site in real time on a display device, said endoscopic images being captured using a camera associated with an endoscopic instrument, and tracking a movement of one or both hands of said teaching surgeon and/or a device held by said teaching surgeon, using a real-time tracking apparatus, wherein said real-time tracking apparatus comprises a tracking system and a computing device, wherein said tracking of said movement comprises recording a sequence of tracking information of one or both hands of said teaching surgeon and/or the device held by said teaching surgeon.
The present invention relates to artificial Antigen Presenting Cells (aAPCs) comprising artificial Antigen Presenting Molecules (aAPMs) and, in particular, comprising dimers of the aAPMs as well as to methods for producing aAPCs. The invention further relates to compositions comprising the aAPCs and to vectors encoding the aAPMs of the aAPCs. Embodiments of the invention have been particularly developed for use in assays for determining an antigen-specific T cell response or a plurality of antigen-specific T cell responses and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
The invention relates to a method for producing an osteotropic bone replacement material from a starting material which substantially has portlandite, calcium oxide, aragonite; calcite and/or apatite. The starting material is introduced into an autoclave with a strontium, fluorine and/or gallium source, wherein when using a starting material which substantially has portlandite, calcium oxide, aragonite; calcite a phosphate source is introduced. In addition, H2O is added into the autoclave as part of a solvent and the pH value in the autoclave is set to a range above 7. Afterwards, the closed and filled autoclave is heated for at least 1 hour and then cooled. The osteotropic bone replacement material thus developed is subsequently cleaned from residues of the phosphorus, strontium, fluorine and/or gallium source. Furthermore, the invention relates to an osteotropic bone replacement material which substantially consists of apatite and in which strontium ions are incorporated into the crystal lattice.
A61L 27/12 - Phosphorus-containing materials, e.g. apatite
C04B 35/447 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on phosphates
15.
APPARATUS CAPABLE OF ACTUATING A DISTAL JOINT AND TRANSFERRING THE CONSTRAINING REACTIONS IN AN UNDERACTUATED SHOULDER EXOSKELETON
Scuola Superiore di Studi Universitari e di Perfezionamanto Sant'Anna (Italy)
Universität Heidelberg (Germany)
Inventor
Masia, Lorenzo
Frisoli, Antonio
Tiseni, Luca
Chiaradia, Domenico
Xiloyannis, Michele
Solazzi, Massimiliano
Abstract
An underactuated mechanism has a first rotoidal joint connected to a human torso and rotating about a first joint rotation axis, a hyper-redundant connection mechanism connected to the first rotoidal joint, and a second rotoidal joint rotating about a second joint rotation axis, coplanar with the first joint rotation axis. The second rotoidal joint is remotely actuated by a driven pulley and Bowden cables or by a direct drive actuation system with co-located motor, and is fixed to the hyper-redundant connection mechanism on one side and to a human arm on the other side. The hyper-redundant connection mechanism has at least three members. Two members of the at least three members are rigidly fixed to one of the rotoidal joints, respectively. All members are connected together by rotation joints with axes parallel to one another and arranged to connect one member to a successive member to form a rotation constraint.
The present invention relates to means and methods for conjugating/attaching target molecules such as proteins to a label and/or carrier. Specifically, the present invention provides a complex comprising a metal cation coordinating (i) nitrate as a metal cation ligand and (ii) a metal cation chelating domain comprising a chelating ligand and a label and/or carrier. This complex can be used for attaching a label and/or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and/or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.
A force measuring plate having a planar regular arrangement of force measuring cells. A force measuring cell is formed in a hole in the force measuring plate, in which hole precisely one planar element which is secured by springs in a self-supporting fashion is arranged and is oriented so as to run parallel to the force measuring plate. Each spring is connected in a materially joined fashion at a first end to the edge of a hole and at a second end to the edge of a planar element. The force measuring plate, the springs and the planar elements are formed from the same material. Each planar element can be elastically deflected in three spatial directions under the effect of a force. There is a linear relationship between the deflection and the force. In addition, the invention relates to a device for determining forces in the piconewton to nanonewton ranges.
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
G01N 33/483 - Physical analysis of biological material
The present invention relates to an apparatus for analyzing single tumor cells, said apparatus comprising a hydrogel-based polymeric microcapsule for entrapping cells and a hydrogel having on its surface a single cell migration path being formed by one or more extracellular matrix proteins and/or one or more polymers comprising RGD peptides or proteins, wherein the polymeric microcapsule and the path are placed in the apparatus such that upon the release of cells from the polymeric microcapsule a single tumor cell can migrate from the polymeric microcapsule on the path.
The present invention relates to compounds that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
21.
METHOD OF CLASSIFYING A SAMPLE BASED ON DETERMINATION OF FGFR
The present invention relates to a method of classifying a sample of a patient that suffers from or being at risk of developing urothelial or bladder cancer, said method comprising the steps of: a) determining in said sample from said patient, the presence or absence of alteration in an FGFR gene and/or the expression level of at least one gene encoding for a receptor selected from the group consisting of FGFR1, FGFR2, FGFR3 or FGFR4, and b) classifying the sample of said patient from the outcome of step a) into one of at least two classifications, said classifications comprising good and poor prognosis for treatment with an anti-cancer agent.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a method for diagnosing or prognosing cancer comprising determining in vitro cytosine methylation levels within marker genes and/or determining expression levels of miRNA markers.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
23.
MIC therapy for specific immunosuppression in transplantation
The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and/or treatment of organ or cell graft rejection in a human graft recipient.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/405 - Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
24.
COMPOUND DECREASING THE CONCENTRATION OF 2-HYDROXY-GLUTARATE
The present invention relates to a compound decreasing the concentration of 2-hydroxy-glutarate (2HG) in a subject for use in treating, preventing, and/or preventing progression of cardiac remodeling, in particular cardiomyopathy and/or heart failure and to viral particles, compositions, uses and methods related thereto.
The present invention relates to a polynucleotide comprising an expressible nucleic acid sequence encoding a relaxin family peptide receptor (RXFP) polypeptide for use in treatment and/or prevention of heart failure in a subject. The present invention further relates to a vector comprising the polynucleotide of the present invention for use in treatment and/or prevention of heart failure, as well as to host cells, RXFP agonists, kits and devices related thereto.
The present invention relates to a method of making an oral dosage form comprising the steps of reacting at least one cell penetrating peptide (CPP), purifying CPP-lipid conjugates, processing a lipid batch to obtain CPP-modified liposomes and incorporating a liposome lyophilisate into an oral dosage form. The present invention further relates to oral dosage forms and oral dosage forms for use in a therapeutic method.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
27.
LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS
The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and -0P03H2, R1 is —CH3 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R2, R3, R4 and R5 are selected from the group consisting of H, —CH2—COOH and —CH2—C(=0)-NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 and w is 1, and wherein A is selected from (la) or (lb), or (C) wherein A is not The compound is disclosed for use in the treatment of PSMA-expressing cancer.
The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and -0P03H2, R1 is —CH3 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R2, R3, R4 and R5 are selected from the group consisting of H, —CH2—COOH and —CH2—C(=0)-NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 and w is 1, and wherein A is selected from (la) or (lb), or (C) wherein A is not The compound is disclosed for use in the treatment of PSMA-expressing cancer.
Described herein is an adeno-associated virus (AAV) capsid polypeptide bonded to a binding peptide including an amino acid sequence RGDX1X2X3X4, with X1 to X4 being independently selected amino acids, for use in treating and/or preventing a muscular disease and/or in muscle regeneration. Also described are polynucleotides, host cells, adeno-associated virus (AAV) capsids, pharmaceutical compositions, uses, and methods related to the AAV capsid polypeptide.
The present invention relates to compositions, methods, and devices for preventing irregular electromechanical waves in the myocardium that lead to pathological conditions as arrhythmia. In particular, the invention relates to compositions and methods to increase the conductivity of the myocardium to restore an impairment of the electrical conduction system of the heart. To that end substances with high conductivity, as carbon nanotube suspensions or metal nanowire suspensions, are injected in the myocardium at closely adjacent locations on circular or open lines or are introduced in patches of cardiomyocytes that are subsequently placed on the myocardium.
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof,
wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II)
wherein X1 is C═O, CH2, C═S, C—OH, C—NH2, or C—NO2, X2 to X4 are independently selected from CH2, C═O, C═S, C—OH, and C—NH2, or R2 is —NH2, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.
C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
The present invention relates to a bioactive compound delivery assembly, a method for stabilization and/or encapsulation of bioactive compound compositions, a method for solid-supported transfection of living cells as well as a use of the bioactive compound delivery assembly.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present invention relates to a polynucleotide encoding a fusion polypeptide comprising an anti-CRISPR (Acr) polypeptide, wherein said fusion polypeptide further comprises a receptor domain changing conformation upon reception of a stimulus. The present invention also relates to a vector comprising the polynucleotide of the present invention, to a bipartite Acr polypeptide comprising a first partial Acr polypeptide comprising amino acids corresponding to amino acids 10 to 62 of SEQ ID NO: 1, and a second partial Acr polypeptide comprising amino acids corresponding to amino acids 67 to 77 of SEQ ID NO: 1, and to a host cell comprising the aforesaid polynucleotide compounds. The present invention also relates to the said compounds for use in medicine, in particular for use in treatment and/or prevention of genetic disease, neurodegenerative disease, cancer, and/or infectious disease. Moreover, the present invention also relates to a kit, methods, and uses related thereto.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present invention relates to an NF-κB inhibitor or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one agent activating the intrinsic pathway of apoptosis; and to an agent activating the intrinsic pathway of apoptosis or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one NF-κB inhibitor. The present invention further relates to combined preparations, medicaments, kits, and methods related thereto.
A body fluid leakage detection aqueous composition, for use e.g. in intraoperative pancreatic fluid leakage detection. The composition comprises a gelling agent, increasing the viscosity of the composition, and buffering species, the composition thereby being buffered. The gelling agent is cross-linked α-glucan microspheres. Further, the composition comprises a pH-indicator. The pH of the composition is at least 0.1 pH units lower, or higher, than a pKa of the pH-indicator.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 17/06 - Needles; Holders or packages for needles or suture materials
G09G 5/02 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the way in which colour is displayed
A method for the identification of compounds modulating the biological activity of FGF2, the method comprising the use of target cells sensitive to the presence of FGF2 by obstructing proliferation, wherein the target cells constitutively express a first reporter in- the nucleus of living target cells.
A computer-implemented method for testing ocular drug delivery is provided. The ocular drug delivery is characterized by a set of delivery parameters comprising at least one of drug type, drug concentration, drug amount, injection position, penetration depth. The method comprises: providing a model for the human eye, wherein the model comprises: a geometry equation defining a three-dimensional generalized limacon for the geometry of the vitreous body, geometry equations describing all components of the eye; and a set of equations defining a drug convection in the vitreous body; setting a target drug state in the vitreous body; using the model to perform at least one simulation of the ocular drug delivery with a given set of values for the set of delivery parameters, wherein the at least one simulation provides a simulated drug state in the vitreous body; comparing the target drug state and the simulated drug state.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
B33Y 80/00 - Products made by additive manufacturing
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
URGO RECHERCHE INNOVATION ET DEVELOPPEMENT (France)
UNIVERSITÄT HEIDELBERG (Germany)
Inventor
Bouschbacher, Marielle
Steinbrunn, Julien Denis Marie
Lavigne, Louis
Gretz, Norbert
Becker, Anja
Hullen, Andreas
Klapczynski, Anna
Kuch, Natalia
Mu, Yifei
Abstract
A light source device including a light emitting element for emitting a light having the following characteristics: a wavelength ranging from 435 to 520 nm, and a power density greater than 20 mW/cm2, the light source device provides an effective fluence to any contaminating and/or pathogenic agent greater than 11 J/cm2. Also, a light source assembly including a product adapted to be in contact with a support or a medium, preferably the skin or a wound and a light source device connected to the product for providing light to at least one contaminating and/or pathogenic agent present on a support or in a medium.
A23L 3/26 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by irradiation without heating
C02F 1/30 - Treatment of water, waste water, or sewage by irradiation
40.
Delta-like ligand 1 for diagnosing severe infections
The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.
The present invention relates to a polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide and (ii) an miRNA target sequence and to vectors and host cells related thereto. The present invention further relates to a kit comprising (I) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide and (ii) an RNA-interference (RNAi) target sequence; and a Cas nuclease or a second polynucleotide comprising an expressible gene encoding a Cas nuclease; (II) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide and (ii) an RNA-interference (RNAi) target sequence, said first polynucleotide further comprising an expressible gene encoding a first fragment of a Cas nuclease, and a second polynucleotide comprising an expressible gene encoding a second fragment of a Cas nuclease, wherein said first and second fragment of said Cas nuclease together reconstitute an active Cas nuclease; or (III) a first polynucleotide comprising (i) a sequence encoding an anti-CRISPR (Acr) polypeptide, (ii) an RNA-interference (RNAi) target sequence, and (iii) a sequence encoding a Cas nuclease; and a second polynucleotide comprising an expressible gene encoding an inhibitory RNA, preferably a siRNA or a miRNA hybridizing to said RNAi target sequence, more preferably a siRNA hybridizing to said RNAi target sequence. Further, the present invention relates to methods and uses related to the aforesaid means.
The present invention relates to a binding polypeptide specifically binding to an epitope comprised in an amino acid sequence corresponding to amino acids 250 to 300 of the norovirus genotype II.10 capsid polypeptide, and to a polynucleotide encoding the same. The present invention further relates to a composition comprising the binding polypeptide according to the present invention and a carrier, and to the binding polypeptide or the composition comprising the same use in diagnosis and/or for use in medicine. Further more, the present invention relates to kits, devices, vaccines, methods, and uses related to the binding polypeptide of the present invention.
The European Atomic Energy Community (EURATOM), Represented by the European Commission (Belgium)
Universität Heidelberg (Germany)
Inventor
Morgenstern, Alfred
Bruchertseifer, Frank
Apostolidis, Christos
Haberkorn, Uwe
Giesel, Frederik
Kratochwil, Clemens
Abstract
The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.
A body fluid leakage detection aqueous composition, for use e.g. in intraoperative pancreatic fluid leakage detection. The composition comprises a gelling agent, increasing the viscosity of the composition, and buffering species, the composition thereby being buffered. The gelling agent is cross-linked α-glucan microspheres. Further, the composition comprises a pH-indicator. The pH of the composition is at least 0.1 pH units lower, or higher, than a pKa of the pH-indicator.
A61B 17/06 - Needles; Holders or packages for needles or suture materials
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
The present invention relates to compounds that have the capability of inhibiting the secretion of fibroblast growth factor 2 (FGF2) by tumor cells, as well as uses of said compound in medicine, in particular in the prevention and/or treatment of cancerous or inflammatory diseases.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A layer having individual elements made of an elastic material, with the length thereof exceeding the diameter thereof, which are secured on a carrier at a distance to one another, wherein the elements can be moved towards and away from one another, the elements can contact when moving towards one another, the outer surfaces of the elements provided with a surface modification, and the surface modification containing substances that can form reversible, non-covalent bonds. Also, a method for producing the layer, and the use of the layer.
The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/00 - Medicinal preparations characterised by special physical form
Multispectral imaging of samples, in particular of biological tissues. A method for acquisition of fluorescence images and reflection images of an object including alternatingly illuminating the object with at least a first light and a second light, wherein the first light and the second light are spectrally shaped such that at least one light has several spectral regions of high light intensity separated by spectral region(s) of low light intensity, wherein the spectral regions of the first light and the second light with high intensity at least partially do not overlap and wherein at least one of the two lights has at least one region of low light intensity that is of longer wavelength to the neighboring region of high light intensity, and recording at least a first image of the object and a second image of the object while illuminating the object with at least one of the lights.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
G01J 3/32 - Investigating bands of a spectrum in sequence by a single detector
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 3/14 - Arrangements specially adapted for eye photography
Multispectral imaging of samples, in particular of biological tissues. A method for acquisition of fluorescence and reflectance images of an object including alternatingly illuminating the object with at least a first light having several spectral regions of high intensity, wherein the first light has at least one region of low intensity that is of longer wavelength to a region of high intensity, and at least a second light having at least one spectral region of high intensity, recording a first image of the object during illumination of the object with the first light and a second image of the object during illumination of the object with the second light using a common sensor array, wherein the light recorded by the sensor array is attenuated in at least one of the spectral regions in which the first light has high intensities.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 3/14 - Arrangements specially adapted for eye photography
A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases or of relapse or local recurrence in tumor related diseases in a mammal and the provision of a therapy recommendation for a patient the enzyme activity of key enzymes of the energy metabolism is determined in fresh tumor tissue or fresh tumor cell mass after 24 hours incubation in a cell culture medium. Incubation reduces nutrition, drug and biopsy/surgery effects on the energy metabolism of the tissue slices or the cell mass. The quotients of enzyme activity of anaerobic enzymes are put in ratio to the enzyme activity of aerobic enzymes or vice versa. Said ratio can be taken into account for prognosis of metastasis and a therapy recommendation.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
The present invention relates to shortened peptides comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptides for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical compositions comprising said peptides and a method for treating or preventing disorders associated with muscular malfunction using said peptides or said pharmaceutical compositions.
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
53.
Total internal reflection interferometer with laterally structured illumination
A total internal reflection microscope for epi-fluorescence illumination observations includes an objective through which an object to be observed is illuminated by an excitation illumination light at an angle to an observation axis of the microscope. The angle is adjustable to be within the range suitable for a total internal reflection observation. The microscope also has a source of collimated excitation light. An interferometer is arranged in the optical path of the collimated excitation light and is configured to produce an interference pattern. A focusing lens system focuses the interference pattern produced by the interferometer into the back focal plane of the objective. The objective and the focusing lens system image the interference pattern produced by the interferometer into the conjugated image plane of the objective, thereby producing excitation illumination light that modulated spatially in intensity in a plane orthogonal to the observation axis of the microscope.